Select Publications
Book Chapters
2015, 'Tetracyclines and Their Use in Autoimmune Bullous Diseases and Epidermolysis Bullosa', in Blistering Diseases: Clinical Features, Pathogenesis, Treatment, Springer Link, pp. 501 - 505, http://dx.doi.org/10.1007/978-3-662-45698-9_50
,2015, 'The Pathogenesis, Assessment and Management of Pruritus in Autoimmune Bullous Diseases', in Blistering Diseases: Clinical Features, Pathogenesis, Treatment, Springer Link, pp. 643 - 649, http://dx.doi.org/10.1007/978-3-662-45698-9_69
,2015, 'The Treatment of Pemphigus Vulgaris and Pemphigus Foliaceus', in Blistering Diseases: Clinical Features, Pathogenesis, Treatment, Springer Link, pp. 533 - 541, http://dx.doi.org/10.1007/978-3-662-45698-9_54
,2015, 'Treatment and Prevention of Glucocorticoid-Induced Osteoporosis', in Blistering Diseases: Clinical Features, Pathogenesis, Treatment, Springer Link, pp. 593 - 603, http://dx.doi.org/10.1007/978-3-662-45698-9_63
,2015, 'Treatment of Dermatitis Herpetiformis', in Blistering Diseases: Clinical Features, Pathogenesis, Treatment, Springer Link, pp. 573 - 578, http://dx.doi.org/10.1007/978-3-662-45698-9_60
,2015, 'Treatment of EB Complications: Esophageal Strictures, Pseudosyndactyly, Urethral and Meatal Stenosis, and Laryngeal Stenosis', in Blistering Diseases: Clinical Features, Pathogenesis, Treatment, Springer Link, pp. 687 - 694, http://dx.doi.org/10.1007/978-3-662-45698-9_72
,2015, 'Using Intravenous Immunoglobulins in Autoimmune Bullous Diseases', in Blistering Diseases: Clinical Features, Pathogenesis, Treatment, Springer Link, pp. 515 - 521, http://dx.doi.org/10.1007/978-3-662-45698-9_52
,2014, 'Pemphigus', in Evidence-Based Dermatology: Third Edition, pp. 552 - 560, http://dx.doi.org/10.1002/9781118357606.ch65
,2011, 'Erythema Multiforme, Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis', in Harper's Textbook of Pediatric Dermatology, Wiley, pp. 78.1 - 78.8, http://dx.doi.org/10.1002/9781444345384.ch78
,2011, 'Diagnosis and Prevention of Bullous Diseases', in Preventive Dermatology in Infectious Diseases, Springer London, pp. 53 - 73, http://dx.doi.org/10.1007/978-0-85729-847-8_6
,2009, 'The Cochrane Skin Group', in Evidence-Based Dermatology: Second Edition, pp. 20 - 25, http://dx.doi.org/10.1002/9781444300161.ch4
,2003, 'Interventions for bullous pemphigoid', in The Cochrane Library, John Wiley & Sons, UK
,2003, 'Interventions for mucous membrane pemphigoid and epidermolysis bullosa acquisita (Cochrane Review)', in Cochrane Database of Systematic Reviews, John Wiley & Sons Ltd, England
,2003, 'The Cochrane Skin Group', in Williams H; Bigby M; Diepgen T; Herxheimer A; Naldi L; Rzany B (ed.), Evidence-based Dermatology, BMJ Publishing Group, London, UK, pp. 24 - 32
,Journal articles
2024, '“Quality of Life in Epidermolysis Bullosa” and “Epidermolysis Bullosa Burden of Disease”: Italian translation, cultural adaptation, and pilot testing of two disease-specific questionnaires', Italian Journal of Pediatrics, 50, http://dx.doi.org/10.1186/s13052-024-01657-2
,2024, 'Digital twins in dermatology, current status, and the road ahead', npj Digital Medicine, 7, http://dx.doi.org/10.1038/s41746-024-01220-7
,2024, 'Safety and tolerability of losartan to treat recessive dystrophic epidermolysis bullosa in children (REFLECT): an open-label, single-arm, phase 1/2 trial', eClinicalMedicine, 77, http://dx.doi.org/10.1016/j.eclinm.2024.102900
,2024, 'Ethics of Publication Mills and Payment for Guaranteed Authorships.', J Am Acad Dermatol, http://dx.doi.org/10.1016/j.jaad.2024.10.034
,2024, 'A Practical Guide to Using Oral JAK Inhibitors for Atopic Dermatitis from the International Eczema Council.', Br J Dermatol, http://dx.doi.org/10.1093/bjd/ljae342
,2024, 'Dermatology Journal Advisory Boards and editorial independence', JAAD International, 16, pp. 224 - 236, http://dx.doi.org/10.1016/j.jdin.2023.08.001
,2024, 'Letter to the editor in reply to “A call for action: Formalin exposure and broader occupational hazards and assessing the risk of glioblastoma in clinician scientists”', Clinics in Dermatology, 42, pp. 526 - 527, http://dx.doi.org/10.1016/j.clindermatol.2024.07.002
,2024, 'Efficacy and Safety of Rilzabrutinib in Pemphigus: PEGASUS Phase 3 Randomized Study', Journal of Investigative Dermatology, 144, pp. 1762 - 1771.e6, http://dx.doi.org/10.1016/j.jid.2024.02.023
,2024, 'Gender equity in academic dermatology: Problems aplenty, yet paths ahead', Journal of the European Academy of Dermatology and Venereology, 38, pp. 1504 - 1513, http://dx.doi.org/10.1111/jdv.20027
,2024, 'Correction to: Study Design of a Phase 2/3 Randomized Controlled Trial of Dupilumab in Adults with Bullous Pemphigoid: LIBERTY-BP ADEPT (Advances in Therapy, (2024), 41, 7, (2991-3002), 10.1007/s12325-024-02810-3)', Advances in Therapy, 41, pp. 3014 - 3015, http://dx.doi.org/10.1007/s12325-024-02886-x
,2024, 'S2k guidelines on diagnosis and treatment of linear IgA dermatosis initiated by the European Academy of Dermatology and Venereology', Journal of the European Academy of Dermatology and Venereology, 38, pp. 1006 - 1023, http://dx.doi.org/10.1111/jdv.19880
,2024, 'Impairment of sexual function in patients with pemphigus', Journal of the European Academy of Dermatology and Venereology, 38, pp. 643 - 644, http://dx.doi.org/10.1111/jdv.19882
,2024, 'The road to publication: Advice from journal editors', Journal of the American Academy of Dermatology, 90, pp. 707 - 710, http://dx.doi.org/10.1016/j.jaad.2023.11.038
,2024, 'Meeting report: Women’s Dermatology Society Forum at the 25th World Congress of Dermatology, Singapore, 2023', International Journal of Women's Dermatology, 10, http://dx.doi.org/10.1097/JW9.0000000000000125
,2024, 'A call for action: Formalin exposure and broader occupational hazards and assessing the risk of glioblastoma in clinician scientists', Clinics in Dermatology, http://dx.doi.org/10.1016/j.clindermatol.2024.05.008
,2024, 'Atypical fixed drug eruption in confetti due to paracetamol', Dermatologica Sinica, 42, pp. 160 - 161, http://dx.doi.org/10.4103/ds.DS-D-23-00161
,2024, 'Autoimmune blistering diseases treated with glucocorticoids: An international study of steroid-induced myopathy', Journal of the European Academy of Dermatology and Venereology, http://dx.doi.org/10.1111/jdv.20149
,2024, 'Bullous pemphigoid burden of disease, management and unmet therapeutic needs', Journal of the European Academy of Dermatology and Venereology, http://dx.doi.org/10.1111/jdv.20313
,2024, 'Cross-sectional burden-of-illness study in atopic dermatitis (MEASURE-AD) in Australia and New Zealand reveals impacts on well-being', Australasian Journal of Dermatology, http://dx.doi.org/10.1111/ajd.14308
,2024, 'Environmental triggers of pemphigus vulgaris and bullous pemphigoid: a case control study', Frontiers in Medicine, 11, http://dx.doi.org/10.3389/fmed.2024.1441369
,2024, 'Pathophysiology of Bullous Pemphigoid: Role of Type 2 Inflammation and Emerging Treatment Strategies (Narrative Review)', Advances in Therapy, http://dx.doi.org/10.1007/s12325-024-02992-w
,2024, 'Predatory Conferences and Journals in Dermatology Are Black Widow Parties', Skinmed, 22, pp. 407 - 408
,2024, 'The development and validation of an investigator global assessment score for keratosis pilaris', Journal of the European Academy of Dermatology and Venereology, http://dx.doi.org/10.1111/jdv.20326
,2024, 'A Case of Hidradenitis Suppurativa Responsive to Testosterone Replacement Therapy.', Indian Dermatol Online J, 15, pp. 854 - 855, http://dx.doi.org/10.4103/idoj.idoj_653_23
,2023, 'Tildrakizumab for the treatment of hidradenitis suppurativa in patients previously treated with adalimumab: A 30-month experience', Clinical and Experimental Dermatology, 48, pp. 1266 - 1269, http://dx.doi.org/10.1093/ced/llad215
,2023, 'Lack of effect of benralizumab on signs and symptoms of moderate-to-severe atopic dermatitis: Results from the phase 2 randomized, double-blind, placebo-controlled HILLIER trial', Journal of the European Academy of Dermatology and Venereology, 37, pp. e1211 - e1214, http://dx.doi.org/10.1111/jdv.19195
,2023, 'Once-daily roflumilast foam 0.3% for scalp and body psoriasis: a randomized, double-blind, vehicle-controlled phase IIb study', British Journal of Dermatology, 189, pp. 392 - 399, http://dx.doi.org/10.1093/bjd/ljad182
,2023, 'The Importance of Patient-Focused Drug Development in Pemphigus and Pemphigoid', Journal of Investigative Dermatology, 143, pp. 1868 - 1871, http://dx.doi.org/10.1016/j.jid.2023.03.1673
,2023, 'Evaluation of skin of color publication trends over the past 2 decades in the Journal of the American Academy of Dermatology', Journal of the American Academy of Dermatology, 89, pp. 614 - 616, http://dx.doi.org/10.1016/j.jaad.2023.05.036
,2023, 'Immunisation status during biologic therapy for hidradenitis suppurativa and psoriasis', JEADV Clinical Practice, 2, pp. 549 - 552, http://dx.doi.org/10.1002/jvc2.182
,2023, 'Interventions for bullous pemphigoid', Cochrane Database of Systematic Reviews, 2023, http://dx.doi.org/10.1002/14651858.CD002292.pub4
,2023, 'A Review of the Scoring and Assessment of Keratosis Pilaris', Skin Appendage Disorders, 9, pp. 241 - 251, http://dx.doi.org/10.1159/000529487
,2023, 'Dermatoethics: Nepotism in dermatology residencies', Journal of the American Academy of Dermatology, 89, pp. 193 - 194, http://dx.doi.org/10.1016/j.jaad.2022.01.011
,2023, 'Efficacy and safety of etrasimod, a sphingosine 1-phosphate receptor modulator, in adults with moderate-to-severe atopic dermatitis (ADVISE)', Journal of the European Academy of Dermatology and Venereology, 37, pp. 1366 - 1374, http://dx.doi.org/10.1111/jdv.18914
,2023, 'The Glucocorticoid Toxicity Index-Metabolic Domains, an abridged version of the Glucocorticoid Toxicity Index: post-hoc analysis of data from the ADVOCATE trial', The Lancet Rheumatology, 5, pp. e413 - e421, http://dx.doi.org/10.1016/S2665-9913(23)00131-5
,2023, 'BG04 Oleogel-S10 (birch triterpenes) in the treatment of epidermolysis bullosa wounds: 24-month efficacy and safety data from the EASE study', British Journal of Dermatology, 188, http://dx.doi.org/10.1093/bjd/ljad113.144
,